Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analysis of the disproportionate metabolite data from the completed Phase 1 multi-ascending dose ("MAD") clinical trial revealed that PBI-4050 (fezagepras) primary metabolite was a glutamine conjugate.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
Details : Fezagepras is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperammonemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBV152
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Ocugen
Deal Size : Undisclosed
Deal Type : Acquisition
Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada
Details : This site would enable Ocugen to expand its manufacturing and research and development capabilities to support its pipeline. This includes the manufacture of COVAXIN™ (BBV152), the company’s COVID-19 vaccine candidate.
Product Name : Covaxin
Product Type : Vaccine
Upfront Cash : Undisclosed
January 27, 2022
Lead Product(s) : BBV152
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Ocugen
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Fezagepras
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras
Details : Based on interim pharmacokinetic results from the ongoing fezagepras multiple ascending dose study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in H...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Fezagepras
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Kedrion
Deal Size : $22.0 million
Deal Type : Divestment
Details : Kedrion will enter into an option agreement with Liminal BioSciences to acquire the remainder of the company’s plasma-derived business, as well as Plasminogen business operated through its subsidiaries including Prometic Biotherapeutics which holds the...
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Undisclosed
May 17, 2021
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Kedrion
Deal Size : $22.0 million
Deal Type : Divestment
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Divestment
Kedrion enters into Agreement with Liminal BioSciences
Details : According to terms and conditions, the Option would grant Kedrion the right to acquire all of the shares of PBP and PBT and would entitle Liminal BioSciences to receive up to seventy percent of the net proceeds, if granted, associated with a potential FD...
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Undisclosed
May 17, 2021
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Divestment
Lead Product(s) : Fezagepras
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Healthy Volunteer Study of PBI-4050
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2021
Lead Product(s) : Fezagepras
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two posters were presented that highlighted individual case histories of patients with C-PLGD treated with the investigational intravenous Ryplazim® (plasminogen) in compassionate use and expanded access cases.
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Inapplicable
December 07, 2020
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(Plasminogen) BLA
Details : The BLA resubmission for Ryplazim® was supported by data from a Phase 2/3 clinical trial, which evaluated 15 patients, both pediatric and adults, with C-PLGD over 48 weeks of therapy with Ryplazim®.
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Two abstracts related to the Company’s clinical development activities of Ryplazim® for the treatment of Congenital Plasminogen Deficiency will be presented at the 62nd American Society of Hematology Annual Meeting and Exposition scheduled to take pla...
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Plasminogen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable